Invest in intelligence that delivers

‘The most challenging disease’: Misdiagnoses, unmet needs abound in systemic sclerosis

Systemic sclerosis is the most challenging diagnosis to make among rheumatic and autoimmune conditions, according to 91% of respondents in a market analysis from Spherix Global Insights. “I agree with the survey responses in that the rheumatologists highlighted systemic sclerosis as the most challenging diagnosis and the most challenging disease to manage in practice,” Dinesh Khanna, MD, MSc, professor […]

Survey: U.S. Derms and Rheums Report “Extremely High” Unmet Need for New Treatments in DM

More than half of dermatomyositis patients are not optimally managed, according to a survey of 102 U.S. rheumatologists and dermatologists by Spherix Global Insights. Currently, the standard of care predominantly involves corticosteroids, topical therapies, traditional disease-modifying anti-rheumatic drugs (tDMARDs), and, in more severe or refractory cases, intravenous immunoglobulin (IVIg) or off-label biologics, underscoring the growing […]

US Rheumatologists and Dermatologists Report Over Half of their Dermatomyositis Patients Not Optimally Managed, According to Spherix Global Insights

Although CSL Behring’s Hizentra (IgPro20) is touted as akey pipeline agent to watch, rheumatologists currently prefer AstraZeneca’sSaphnelo (anifrolumab), while dermatologists favor Priovant Therapeutics’brepocitinib. Exton, PA, October 18, 2024 – Dermatomyositis (DM) is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. Currently, the standard of care predominantly involves corticosteroids, topical therapies, […]

Roche/Genentech’s Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

Following positive topline results from the Phase III REGENCY trial, Gazyva is positioned to compete with Benlysta and Lupkynis in the lupus nephritis treatment landscape, pending approval.  EXTON, PA., October 10, 2024 – While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a serious […]

US Rheumatologists Identify BAFF-R Inhibitors as the Most Promising Treatment Approach for Sjögren’s Disease, According to Spherix Global Insights 

Despite keen interest in BAFF-R inhibition, rheumatologists favor BMS’ Sotyktu (deucravacitinib) as the leading therapy in development for Sjögren’s.  EXTON, PA., October 02, 2024 — Sjögren’s disease is a systemic autoimmune rheumatic condition that can profoundly affect a patient’s overall functioning. Common symptoms include significant dryness, particularly in the eyes and mouth, along with severe […]

Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights

US gastroenterologists more in favor of biosimilars than rheumatology and dermatology counterparts. EXTON, PA., September 23, 2024 — Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late April 2024 (n=104 gastroenterologists, 103 rheumatologists, and 106 dermatologists), to provide an updated perspective on adalimumab biosimilar […]

Lupus landscape ‘poised for evolution’ as US doctors eagerly await new entrants

Biogen’s litifilimab “stands out as an especially strong competitor” to Benlysta and Saphnelo, according to Spherix Global Insights analysts. New biologics such as GSK’s Benlysta and AstraZeneca’s Saphnelo, along with off-label drugs, have been the mainstay for systemic lupus erythematosus (SLE) treatment for many years. However, the landscape may be about to change with the […]

US Rheumatologists Believe Biogen’s Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data  

Despite favorable views on litifilimab, AbbVie’s Rinvoqand BMS’ Sotyktu capture the most prescriber interest for approval, accordingto Spherix Global Insights. EXTON, PA., September 12, 2024 — The systemic lupus erythematosus (SLE) advanced treatment landscape is poised for evolution, with multiple new therapies in development to treat this debilitating and chronic disease. While Biogen’s litifilimab has […]

‘Exciting time’: Biologic use in moderate to severe lupus rose 45% since 2021

Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights. The analysis additionally found that nearly half of moderate-to-severe patients with SLE are currently on a biologic. Meanwhile, among those not currently on a biologic, […]

Sign up for alerts, market insights and exclusive content in your inbox.